Robert W. Baird Forecasts Strong Price Appreciation for Oculis (NASDAQ:OCS) Stock

Oculis (NASDAQ:OCS - Get Free Report) had its price target raised by stock analysts at Robert W. Baird from $37.00 to $41.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage presently has an "outperform" rating on the stock. Robert W. Baird's price target indicates a potential upside of 117.62% from the company's previous close.

OCS has been the subject of several other reports. HC Wainwright reduced their price objective on Oculis from $30.00 to $29.00 and set a "buy" rating for the company in a report on Thursday. Chardan Capital reiterated a "buy" rating and issued a $28.00 price target on shares of Oculis in a research note on Thursday.

Oculis Trading Up 2.4 %

Shares of NASDAQ OCS opened at $18.84 on Thursday. The company has a market cap of $763.10 million, a PE ratio of -9.76 and a beta of 0.02. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.02 and a current ratio of 4.02. The firm's 50 day moving average price is $20.82 and its 200-day moving average price is $16.86. Oculis has a 52-week low of $10.55 and a 52-week high of $23.08.

Oculis (NASDAQ:OCS - Get Free Report) last issued its earnings results on Tuesday, March 11th. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.28). Oculis had a negative net margin of 8,043.28% and a negative return on equity of 71.31%. On average, equities research analysts expect that Oculis will post -2.09 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of OCS. abrdn plc grew its stake in shares of Oculis by 23.0% during the 4th quarter. abrdn plc now owns 1,009,424 shares of the company's stock valued at $17,150,000 after purchasing an additional 188,871 shares during the period. Bank of America Corp DE grew its position in Oculis by 58.2% during the fourth quarter. Bank of America Corp DE now owns 28,980 shares of the company's stock valued at $493,000 after buying an additional 10,667 shares during the period. Citadel Advisors LLC bought a new stake in Oculis during the fourth quarter valued at approximately $389,000. Geode Capital Management LLC increased its holdings in Oculis by 12.0% during the fourth quarter. Geode Capital Management LLC now owns 16,744 shares of the company's stock valued at $284,000 after buying an additional 1,800 shares during the last quarter. Finally, XTX Topco Ltd bought a new position in Oculis in the fourth quarter worth approximately $225,000. Institutional investors own 22.30% of the company's stock.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Remove Ads